Intranasal sufentanil for cancer-associated breakthrough pain

Abstract

The objective of this study was to demonstrate the efficacy, safety and patient acceptability of the use of intranasal sufentanil for cancer-associated breakthrough pain. This was a prospective, open label, observational study of patients in three inpatient palliative care units in Australia. Patients on opioids with cancer-associated breakthrough pain and clinical evidence of opioid responsiveness to their breakthrough pain were given intranasal (IN) Sufentanil via a GO Medical™ patient controlled IN analgesia device. The main outcome measures were pain scores, need to revert to previous breakthrough opioid after 30 min, number of patients who chose to continue using IN sufentanil, and adverse effects. There were 64 episodes of use of IN sufentanil for breakthrough pain in 30 patients. There was a significant reduction in pain scores at 15 (P < 0.0001) and 30 min (P < 0.0001). In only 4/64 (6%) episodes of breakthrough pain did the participants choose to revert to their prestudy breakthrough medication. Twenty-three patients (77%) rated IN sufentanil as better than their prestudy breakthrough medication. The incidence of adverse effects was low and most were mild. Our study showed that IN sufentanil can provide relatively rapid onset, intense but relatively short lasting analgesia and in the palliative care setting it is an effective, practical, and safe option for breakthrough pain.

Keywords

breakthrough pain cancer opioid sufentanil

Get full access to this article

View all access options for this article.

References

1 Portenoy RK Hagen NA . Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41: 273–281.

2 Therapeutic Guidelines Limited . Palliative Care Expert Group. Therapeutic guidelines: palliative care. 2nd ed. North Melbourne, Vic.: Therapeutic Guidelines Ltd; 2005.

3 Stanley TH . The history and development of the fentanyl series. J Pain Symptom Manage 1992; 7(Suppl. 3): S3–S7.

4 Helmers JH Noorduin H Van Peer A Van Leeuwen L Zuurmond WW . Comparison of intravenous and intranasal sufentanil absorption and sedation. Can J Anaesth 1989; 36: 494–497.

5 Zeppetella G . An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage 2000; 20: 253–258.

6 Zeppetella G . Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain. Palliat Med 2000; 14: 57–58.

8 Jackson K Ashby M Keech J . Pilot dose finding study of intranasal sufentanil for breakthrough and incident cancer-associated pain. J Pain Symptom Manage 2002; 23: 450–452.

9 O’Neil G Paech M Wood F . Preliminary clinical use of a patient-controlled intranasal analgesia (PCINA) device. Anaesth Intensive Care 1997; 25: 408–412.

10.

10 Farrar JT Portenoy RK Berlin JA Kinman JL Strom BL . Defining the clinically important difference in pain outcome measures. Pain 2000; 88: 287–294.

11.

11 Streisand JB Varvel JR Stanski DR Le Maire L Ashburn MA Hague BI . Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991; 75: 223–229.

12.

12 Portenoy RK Payne R Coluzzi P Raschko JW Lyss A Busch MA . Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999; 79: 303–312.